Nick Defilippo

Nick brings over 15 years of experience in the healthcare technology space, with the past 8 years being focused solely on precision medicine. Prior to joining Genomics, Nick held various leadership roles at Helix, most recently leading strategy and business development across a number of business segments. The role included engagement with large provider networks, payors, pharmaceutical companies, life science companies and large retail pharmacies. Prior to Helix, Nick was one of the first commercial hires for GRAIL, a multi-cancer liquid biopsy company that raised over $2 billion USD before being purchased by Illumina. Earlier in his career, Nick held sales and strategy leadership roles for early stage digital health start-ups and spent 3 years with Myriad Genetics. In his role as Chief Commercial Officer, Nick will be based in the US.